An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up
Latest Information Update: 04 Mar 2026
At a glance
- Drugs AMG 732 (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 04 Mar 2026 New trial record